Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Squamous Cell Carcinoma of Head and Neck 5Skin Neoplasms 5Neoplasm Metastasis 5Melanoma 5Lung Neoplasms 5Carcinoma 5Recurrence 4Neoplasms 4Mouth Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Vaccinia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1

Interventions

Nivolumab 37pembrolizumab 26cabozantinib 26Specimen Handling 23Magnetic Resonance Spectroscopy 21Ipilimumab 19lenvatinib 13belzutifan 13Axitinib 13CTLA-4 Antigen 10Sunitinib 9Radiosurgery 8Biopsy 8atezolizumab 7fludarabine 4avelumab 4aldesleukin 4Immunoglobulin G 4Disulfides 4zimberelimab 3toripalimab 3tivozanib 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3Surveys and Questionnaires 3Nephrectomy 3Everolimus 3Cyclophosphamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × cemiplimab × 90 days × Clear all
NCT07594106 2026-05-18

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
265 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07188896 2026-05-01

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Hoosier Cancer Research Network

Phase 2 Recruiting
120 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06413680 2026-04-28

BrILliance

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
240 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡